Anzeige
Mehr »
Freitag, 19.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AP32 | ISIN: US74366E1029 | Ticker-Symbol: PGF
Berlin
18.09.25 | 21:52
52,00 Euro
+4,00 % +2,00
1-Jahres-Chart
PROTAGONIST THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PROTAGONIST THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
52,5053,0018.09.

Aktuelle News zur PROTAGONIST THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PROTAGONIST THERAPEUTICS Aktie jetzt für 0€ handeln
MiDemystifying Protagonist Therapeutics: Insights From 4 Analyst Reviews1
MiProtagonist Therapeutics, Inc. (PTGX): A Bull Case Theory2
MiThis Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday2
MiProtagonist Therapeutics: Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress144Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studiesIcotrokinra also showed sustained...
► Artikel lesen
MoProtagonist Therapeutics: Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025234NEWARK, CALIFORNIA / ACCESS Newswire / September 15, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in...
► Artikel lesen
12.09.This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday1
11.09.Protagonist Therapeutics: Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency258Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3 studies that met all primary and co-primary endpoints....
► Artikel lesen
26.08.Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025256NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer...
► Artikel lesen
25.08.Protagonist Therapeutics: Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera298Breakthrough Therapy designation complements Rusfertide's Orphan Drug and Fast Track designations, which together confer multiple benefits to the development programU.S. New Drug Application filing...
► Artikel lesen
07.08.What 4 Analyst Ratings Have To Say About Protagonist Therapeutics2
07.08.Protagonist Therapeutics stock price target raised to $69 by JMP1
06.08.Protagonist Therapeutics, Inc - 10-Q, Quarterly Report3
06.08.Protagonist Therapeutics: Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update295NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in JulyANTHEM Phase 2b trial data of icotrokinra...
► Artikel lesen
06.08.Protagonist Therapeutics, Inc - 8-K, Current Report4
21.07.Protagonist Therapeutics: Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis342Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptorFiling based on unprecedented data package that met all primary endpoints across four...
► Artikel lesen
01.07.H.C. Wainwright reiterates Buy rating on Protagonist Therapeutics stock17
30.06.Protagonist Therapeutics: Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity334A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptorsCompany...
► Artikel lesen
26.06.Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate264Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the...
► Artikel lesen
20.06.Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity13
17.06.Citi initiates Protagonist Therapeutics stock with buy rating on drug potential1
Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1